Drug Patents owned by Astellas
1. List of Cresemba drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10812238 | ASTELLAS | Configurable reference signals |
Oct, 2025
(2 years from now) | |
| US6812238 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10206879 | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Sep, 2027
(4 years from now) | |
| US10603280 | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Sep, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 6, 2020 |
| ODE* (ODE*) | Mar 6, 2022 |
| Orphan Drug Exclusivity (ODE) | Mar 6, 2022 |
| Generating Antibiotic Incentives Now (GAIN) | Mar 6, 2027 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: 2026-03-06
Market Authorisation Date: 06 March, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
2. List of Lexiscan drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6403567 | ASTELLAS | N-pyrazole A2A adenosine receptor agonists |
Apr, 2022
(1 year, 1 month ago) | |
| US8106183 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47301 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(3 years from now) | |
Drugs and Companies using REGADENOSON ingredient
Market Authorisation Date: 10 April, 2008
Treatment: Method for stimulating coronary vasodilation for purposes of imaging the heart
Dosage: SOLUTION;INTRAVENOUS
3. List of Vesicare Ls drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9918970 | ASTELLAS | Pharmaceutical composition comprising solifenacin |
May, 2031
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | May 26, 2023 |
| Pediatric Exclusivity (PED) | Nov 26, 2023 |
Drugs and Companies using SOLIFENACIN SUCCINATE ingredient
Market Authorisation Date: 26 May, 2020
Treatment: NA
Dosage: SUSPENSION;ORAL
4. List of Xospata drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8969336 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jan, 2031
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9487491 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jul, 2030
(7 years from now) | |
| US10786500 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 28, 2025 |
| New Chemical Entity Exclusivity (NCE) | Nov 28, 2023 |
Drugs and Companies using GILTERITINIB FUMARATE ingredient
NCE-1 date: 2022-11-28
Market Authorisation Date: 28 November, 2018
Treatment: Treatment of acute myeloid leukemia (aml)
Dosage: TABLET;ORAL
XOSPATA family patents
7
Japan
6
United States
3
Hungary
3
European Union
2
Poland
2
Canada
2
Slovenia
2
Korea, Republic of
2
Hong Kong
2
Taiwan
2
Lithuania
2
China
2
RS
2
Denmark
2
Croatia
2
Spain
2
Mexico
2
Norway
2
Portugal
2
Russia
2
Cyprus
1
Philippines
1
Luxembourg
1
Brazil
1
Netherlands
1
Australia
1
San Marino
1
South Africa
1
Israel
5. List of Xtandi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7709517 | ASTELLAS | Diarylhydantoin compounds |
Aug, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9126941 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
May, 2026
(2 years from now) | |
| US8183274 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
Aug, 2026
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 16, 2022 |
Drugs and Companies using ENZALUTAMIDE ingredient
Market Authorisation Date: 31 August, 2012
Treatment: The treatment of patients with metastatic castration-sensitive prostate cancer; Treatment of patients with castration-resistant prostate cancer (crpc)
Dosage: CAPSULE;ORAL
XTANDI family patents
23
United States
15
Japan
14
Korea, Republic of
9
New Zealand
8
European Union
6
China
6
Norway
6
Russia
5
Hong Kong
4
Mexico
3
South Africa
3
Singapore
3
Israel
2
Poland
2
Canada
2
Slovenia
2
Brazil
2
RS
2
Denmark
2
Croatia
2
Spain
2
Australia
2
Portugal
2
Cyprus
1
ME
1
Luxembourg
1
Hungary
1
Austria
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic